Bill takes on drug counterfeiters
This article was originally published in The Tan Sheet
Rep. Mike Rogers, R-Mich., introduces legislation March 11 to beef up penalties to deter counterfeiting of prescription and nonprescription drugs. Under the Counterfeit Drug Prevention Act of 2009, H.R. 1450, counterfeit manufacturers and complicit wholesalers would face up to 20 years in prison or, in the event a fake product results in a consumer's death, a life sentence. Rogers says sales of counterfeit drugs by 2010 are expected to reach $75 billion, more than 10 percent of global pharmaceutical sales. Hi-Tech Pharmaceuticals' CEO was sentenced to 50 months in prison for counterfeit drug charges (1"The Tan Sheet" Feb. 9, 2009, In Brief)
You may also be interested in...
Jared R. Wheat is ordered to serve 50 months in federal prison and must forfeit $3 million gained through the production and marketing of counterfeit drugs - including Xanax, Vioxx and Viagra - with other executives from Hi-Tech Pharmaceuticals. Company founder and CEO Wheat, along with his co-conspirators, established a drug manufacturing facility in rural Belize that "complied with none of the sanitary, hygienic or quality-control regulations issued by the FDA," and subsequently sold unauthorized drugs online without a prescription, the Department of Justice says in a Feb. 3 release. Judge Jack T. Camp of the U.S. District Court for the Northern District of Georgia also places the Norcross, Ga.-based supplement firm on five years' probation. A separate case in which Hi-Tech was charged with making false and misleading claims about its supplement products did not play into the criminal prosecution (1"The Tan Sheet" Aug. 25, 2008, p. 7)
A recent court case and an upcoming federal election promise movement in Germany's cannbidiol market, stated Joscha Krauss, CEO of local manufacturer MH Medical Hemp GmbH, at the 18th European Industrial Hemp Association (EIHA) Annual Conference.
Dr Reddy’s has shaken up the market for generic Vascepa in the US by launching its own icosapent ethyl capsules to compete with Hikma’s generic and the Amarin brand, hot on the heels of the Supreme Court’s rejection of the originator’s attempt to overturn a Federal Circuit decision invalidating six Vascepa patents.